Physician profile
Beth Ballen
NPI 1063559334
$1,236.45
in general payments reported to CMS, 2019-2025
19 companies · $543 in 2025
The $543 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $136 · 2021: $32.27 · 2022: $51.40 · 2023: $103 · 2024: $370 · 2025: $543.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,017.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,016.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $204.12 | 2024-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $138.09 | 2024-2025 | Caplyta |
| Axsome Therapeutics, INC. | $136.27 | 2023-2025 | Auvelity |
| Lundbeck LLC | $125.68 | 2022-2024 | Rexulti, Brintellix |
| Janssen Pharmaceuticals, INC | $120.95 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $101.73 | 2024-2025 | Trintellix |
| Abbvie INC. | $75.04 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $68.87 | 2023-2024 | Austedo Xr |
| Sunovion Pharmaceuticals INC. | $48.98 | 2021-2022 | |
| Corium, LLC | $34.16 | 2024 | Azstarys |
| Noven Therapeutics, LLC | $33.75 | 2024 | Xelstrym |
| Otsuka America Pharmaceutical, INC. | $31.55 | 2024 | Rexulti |
| Bausch Health US, LLC | $21.82 | 2025 | Aplenzin |
| Alkermes, INC. | $18.29 | 2024 | Aristada, Lybalvi |
| Braeburn INC. | $17.89 | 2023 | Brixadi |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $15.29 | 2019 | |
| Tempus Ai, INC | $15.05 | 2024 | |
| Idorsia Pharmaceuticals US INC | $14.68 | 2024 | Quviviq |
| Indivior INC. | $14.24 | 2024 | Sublocade |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beth Ballen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.